Last --
Change Today 0.00 / 0.00%
Volume 0.0
1066 On Other Exchanges
1066 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

shandong weigao gp medical-h (1066) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SHANDONG WEIGAO GP MEDICAL-H (1066)

Related News

No related news articles were found.

shandong weigao gp medical-h (1066) Related Businessweek News

No Related Businessweek News Found

shandong weigao gp medical-h (1066) Details

Shandong Weigao Group Medical Polymer Company Limited is engaged in the research and development, production, and sale of medical devices under the Jierui and Wego Ortho brands in the People’s Republic of China and internationally. The company operates through Single Use Medical Device Products, Orthopaedic Products, and Blood Purification Products divisions. It offers single use medical consumables and materials, which include infusion sets, syringes, blood bags and blood component segregator consumables, blood sampling consumables, pre-filled syringes, dental consumables, anesthetic consumables, and medical PVC granules and non-PVC granules, as well as medical needle products comprising intravenous, syringe, intravenous catheter, blood sampling, and irregular needles. The company also provides orthopaedic materials and tools comprising therapeutic consumables, such as steel plates, screws, spinal series consumables, and artificial joints consumables. In addition, it offers blood purification consumables, including renal consumables, such as puncture needles, blood circuits, dialysis equipment, and immunity adsorption products for the treatment of immune system diseases; and other LDL adsorption, internal toxin adsorption, and hepatitis B adsorption products, as well as heart eluting stents, including drug eluting stents and balloon catheters. Further, the company is involved in trading medical products; providing logistics and storage services; and manufacturing moulds, and industrial automatic equipment and parts, as well as provides medical management software development and related technical consulting services. It sells its products to healthcare organizations and distributors, including hospitals, blood stations, and other medical units. The company was founded in 2000 and is based in Weihai, the People’s Republic of China. Shandong Weigao Group Medical Polymer Company Limited is a subsidiary of Weigao Holding Company Limited.

9,304 Employees
Last Reported Date: 04/8/14
Founded in 2000

shandong weigao gp medical-h (1066) Top Compensated Officers

Vice Chairman, General Manager, Compliance Of...
Total Annual Compensation: CNY1.2M
Executive Director
Total Annual Compensation: CNY900.0K
Executive Director
Total Annual Compensation: CNY666.0K
Deputy General Manager of General Affairs and...
Total Annual Compensation: CNY954.0K
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

shandong weigao gp medical-h (1066) Key Developments

Shandong Weigao Group Medical Polymer Company Limited Enters into Five Years Loan Agreement with International Finance Corporation

The board of directors of Shandong Weigao Group Medical Polymer Company Limited (the company or the borrower) announced that the company entered into a five years loan agreement for the principal amount of RMB 600 million with the International Finance Corporation. The company shall repay the loan in one lump sum on 15 March 2020. The Board considers that the loan will facilitate the business development of Weigao Blood Purification Products Company Limited to establish blood dialyzer and related products manufacturing capacity and to open additional hemodialysis centers in China. Under the loan agreement, the borrower has agreed, among other terms and conditions that an event of default will arise if any of the following events, among others occurs: a failure by Weigao Holding Company Limited at any time and for any reason to own at least 35% interests in the borrower's share capital; the Board shall cease to consist of half of continuing executive directors; Mr. Huawei Zhang, shall cease to be an executive director of the borrower; the borrower fails to comply with any of its obligations under the loan agreement and any such failure continues for a period of thirty days after the date on which that failure occurs; any representation or warranty made in the Loan Agreement is found to be incorrect in any material respect; and any of the borrower's shares cease to be listed on the Stock Exchange of Hong Kong Limited.

Shandong Weigao Group Medical Polymer Co. Ltd. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Shandong Weigao Group Medical Polymer Co. Ltd. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenue of RMB 1,253,040,000 compared to RMB 1,238,174,000 a year ago. Profit before taxation was RMB 261,375,000 compared to RMB 398,054,000 a year ago. Profit for the period attributable to owners of the company was at RMB 223,217,000 compared to RMB 347,464,000 a year ago. Earnings per basic share were at RMB 0.050 against RMB 0.078 for the same period in the last year. For the nine months, the company reported revenue of RMB 3,797,605,000 against RMB 3,400,230,000 for the same period last year. Profit before taxation was RMB 819,404,000 compared to RMB 899,821,000 a year ago. Profit for the Period attributable to owners of the company was at RMB 696,118,000 compared to RMB 776,935,000 a year ago. Earnings per basic share were at RMB 0.156 against RMB 0.174 reported last year.

Shandong Weigao Group Medical Polymer Co., Limited to Report Q3, 2014 Results on Nov 19, 2014

Shandong Weigao Group Medical Polymer Co., Limited announced that they will report Q3, 2014 results on Nov 19, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
1066:HK $6.38 HKD +0.01

1066 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1066.
View Industry Companies

Industry Analysis


Industry Average

Valuation 1066 Industry Range
Price/Earnings 73.5x
Price/Sales 4.5x
Price/Book 2.4x
Price/Cash Flow 73.5x
TEV/Sales 3.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHANDONG WEIGAO GP MEDICAL-H, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at